Steatohepatitis diseases treatment needs time action and must be done professionally

Steatohepatitis diseases treatment: Nonalcoholic fatty liver complication

In our previous article we looked at the causes and consequences of nonalcoholic fatty liver diseases (NAFLD) and steatohepatitis disease broadly. Guided by that we want to find treatment solutions of this uncalled for health condition. Whereas prevention is the best approach of all possible health conditions, we often find ourselves suffering from certain health conditions which could have otherwise been prevented. Therefore if you are in anyway suffering from any weight related condition, help is on the way at AWAREmed Health and Wellness Resource Center under Doctor Akoury’s care. Doctor Akoury is an expert of several decades of experience in matters relating to overweight, obesity, addiction and beauty among many other disciplines. She has been of great help to many people across the globe and your situation will be very safe in her care. You can schedule for an appointment with her even as we get into the discussion about treating nonalcoholic fatty liver and nonalcoholic steatohepatitis diseases (NASH) progressively.

Steatohepatitis diseases treatment: NAFLD and NASH

Accumulation of fat in the liver (fatty liver) is common in all stages of nonalcoholic fatty liver disease (NAFLD). The initial stage in the spectrum of nonalcoholic fatty liver disease is fatty liver (steatosis).
The basic cause of nonalcoholic fatty liver disease is insulin resistance, a condition in which the effects of insulin on cells within the body are reduced. The most frequent risk factor for insulin resistance is obesity, especially abdominal obesity.
Fatty liver is itself quite harmless, disappears rapidly with loss of weight, and infrequently progresses to Nonalcoholic steatohepatitis, which is the next stage of nonalcoholic fatty liver disease.
In Nonalcoholic steatohepatitis there is accumulation of fat in the liver, but there also is inflammation (hepatitis), destruction (necrosis) of liver cells, and scarring (fibrosis) of the liver. The scarring can progress to cirrhosis, which is the last stage of nonalcoholic fatty liver disease.
The risk factors, the time-line, and the processes (mechanisms) responsible for progression through the stages of Nonalcoholic fatty liver disease are still unclear.
The presumptive diagnosis of Nonalcoholic fatty liver disease or Nonalcoholic steatohepatitis is made in individuals who are insulin resistant, have mildly elevated liver enzymes in the blood, and have signs of fatty liver on an ultrasound. These patients must have no other cause for the abnormal enzymes or for the fatty liver, particularly no excessive use of alcohol.
If weight loss results in a decrease or normalization of the liver enzymes, the diagnosis of nonalcoholic fatty liver disease is practically assured. Only a liver biopsy, however, can confirm the diagnosis of Nonalcoholic fatty liver disease and Nonalcoholic steatohepatitis and determine the severity of the disease.
Whether or not it is vital to perform a liver biopsy in individuals with suspected nonalcoholic fatty liver disease or nonalcoholic steatohepatitis is still debated among liver specialists since no well-proven treatments are available. A liver biopsy can exclude other liver diseases as the cause of the abnormal tests or fat and provide information about the stage (and therefore the expected outcome) of Nonalcoholic fatty liver disease. It also may provide an incentive for an individual to adopt a healthy lifestyle (diet and exercise) with the aim of losing weight.
Weight loss, if overweight, and correcting elevated cholesterol, triglycerides, and blood sugar should be beneficial in Nonalcoholic fatty liver disease.